ASCO: Affimed pivots to cancer combo after failing to meet monotherapy study continuation criteria

Affimed is rethinking development of its bispecific innate cell engager after getting a look at phase 1/2a monotherapy data. The biotech saw two partial responses in 15 patients, resulting in data that fell short of the continuation criteria but offered enough encouragement for it to plot more combination work.